Recursion Pharms
Stock
Stock
ISIN: US75629V1044
Ticker: RXRX
US75629V1044
RXRX
Price
Price
CHART BY
Frequently asked questions
What is Recursion Pharms's market capitalization?
The market capitalization of Recursion Pharms is $3.63B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Recursion Pharms?
Recursion Pharms's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.528. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Recursion Pharms's stock?
Currently, 7 analysts cover Recursion Pharms's stock, with a consensus target price of $9.00. Analyst ratings provide insights into the stock's expected performance.
What is Recursion Pharms's revenue over the trailing twelve months?
Over the trailing twelve months, Recursion Pharms reported a revenue of $65.18M.
What is the EBITDA for Recursion Pharms?
Recursion Pharms's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$365.25M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Recursion Pharms?
Recursion Pharms has a free cash flow of -$332.29M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
What is the free float of Recursion Pharms's shares?
The free float of Recursion Pharms is 296.92M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $3.63B
- EPS (TTM)
- -$1.528
- Free Float
- 296.92M
- Revenue (TTM)
- $65.18M
- EBITDA (TTM)
- -$365.25M
- Free Cashflow (TTM)
- -$332.29M
Pricing
- 52W span
- $5.61$15.74
Analyst Ratings
The price target is $9.00 and the stock is covered by 7 analysts.
Buy
2
Hold
5
Sell
0
Information
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- US75629V1044
- Primary Ticker
- RXRX
Finance data from FactSet